Lilly Withdraws Yentreve NDA One Day Ahead Of Expected Negative Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Company withdraws its application for the stress urinary incontinence treatment one day ahead of FDA's action date. Discussions with FDA suggested the agency was "not prepared at this time" to approve duloxetine for SUI. NDA withdrawal comes the day after Lilly discussed expected challenges of the Yentreve launch.
You may also be interested in...
Lilly Drops Commercialization Efforts For Yentreve
A year after withdrawing its NDA, Lilly gives up on a stress urinary incontinence indication for duloxetine.
Lilly Drops Commercialization Efforts For Yentreve
A year after withdrawing its NDA, Lilly gives up on a stress urinary incontinence indication for duloxetine.
Lilly Does Not Anticipate Additional Wholesaler Destocking Through 2005
Wholesaler destocking of the ADHD therapy Strattera and the antidepressant Prozac reduced Lilly's U.S. sales by $30 mil. during the quarter, the company says. Sequential increase in Zyprexa sales is indicative of stabilizing prescribing trends for the atypical antipsychotic, Lilly says.